Business Context and Reporting Period
This Form 8-K Current Report was filed by Apimeds Pharmaceuticals US, Inc. on December 30, 2025. The report addresses a corporate governance event involving the removal of a director from the Company's board.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change in board composition and does not contain financial performance data.
Material Changes
On December 30, 2025, stockholders acting by written consent removed Erik Emerson from the Company's board of directors, effective immediately. The removal was executed with or without cause via the affirmative vote of stockholders holding a majority of the outstanding voting shares.
The remaining members of the board of directors are:
- Elona Kogan
- Jakap Koo
- Carol O'Donnell
- Dr. Bennett Weintraub, PHD
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the disclosed board change.
Key Facts for Investor Verification
- Event Date: December 30, 2025.
- Action Taken: Removal of Erik Emerson from the Board of Directors.
- Voting Mechanism: Written consent of stockholders holding a majority of voting power.
- Current Board Composition: Four directors remain (Kogan, Koo, O'Donnell, Weintraub).
- Financial Data: No financial metrics are disclosed in this specific filing.